ConductScience.org, home

Trial · NCT04338061

Participant flow12

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Double-blind Treatment Period: 156 WeeksSTARTEDTeriflunomide583
Double-blind Treatment Period: 156 WeeksSTARTEDEvobrutinib583
Double-blind Treatment Period: 156 WeeksCOMPLETEDTeriflunomide409
Double-blind Treatment Period: 156 WeeksCOMPLETEDEvobrutinib410
Double-blind Treatment Period: 156 WeeksNOT COMPLETEDTeriflunomide174
Double-blind Treatment Period: 156 WeeksNOT COMPLETEDEvobrutinib173
Double-blind Extension Period: 96 WeeksSTARTEDTeriflunomide390
Double-blind Extension Period: 96 WeeksSTARTEDEvobrutinib389
Double-blind Extension Period: 96 WeeksCOMPLETEDTeriflunomide381
Double-blind Extension Period: 96 WeeksCOMPLETEDEvobrutinib377
Double-blind Extension Period: 96 WeeksNOT COMPLETEDTeriflunomide9
Double-blind Extension Period: 96 WeeksNOT COMPLETEDEvobrutinib12

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04338061/flow